

CURRICULUM VITAE

NAME: Michael N. Dworzak, M.D.
DATE OF BIRTH: August 26, 1963
PLACE OF BIRTH: Vienna, Austria
CITIZENSHIP: Austrian
FAMILY STATUS: Married, 3 children

ADDRESS: St. Anna Children´s Hospital
Children´s Cancer Research Institute (CCRI)
Kinderspitalgasse 6, A-1090 Vienna
TELEPHONE: +43-1-40170
FAX: +43-1-40170-7325
E-MAIL: dworzak@stanna.at

MEDICAL TRAINING: University of Vienna, School of Medicine,
Dr. Karl Lueger-Ring, A-1010 Vienna, Austria
GRADUATION: **M.D., July 17, 1988**

POSTDOC EDUCATION:
10-1988 - 06-1990 Research fellowship at the CCRI
07-1990 - 10-1992 Start of post-doctoral medical training: Internship
11-1992 - 02-1993 Research fellowship at the Free University Amsterdam,
NL, Dept. of Pediatrics, Div. of Hemato-Onco-Immunology
(Prof. Dr. A. Veerman – Dr. R. Pieters)
03-1993 - 11-1997 Residency (pediatrics) at St. Anna Kinderspital
(oncological training starting of 11-1993)
since 11-1997 **Consulting physician in pediatrics**
(Facharzt für Kinder- und Jugendheilkunde)

HABILITATION:
10-1999 **Associate Professor of Pediatrics**
(Univ. Dozent für Pädiatrie), Med-Uni Wien
Thesis: “Immunological characterization of physiologic and
malignant B-lymphatic precursor cells in pediatric bone
marrow: development of a method for minimal residual
disease monitoring in ALL”

CURRENT OCCUPATION:
since 03-1993 **Research group leader at the CCRI**
since 11-1997 Consultant clinical oncologist at the St. Anna Kinderspital
since 05-2000 Vice-Coordinator of the Austrian AML-BFM-SG
(Coordinator: Prof. Dr. H. Gadner)
since 06-2000 **Coordinator of the I-BFM-ALL-FCM-MRD-SG**
since 09-2000 Member of the study commission of the AML-BFM-SG
since 11-2001 Head (Oberarzt) of the hemato-oncological day care
department of the St. Anna Kinderspital
since 03-2003 **Coordinator of the Austrian AML-BFM studies**
since 02-2005 **Head (Bereichsleitender Oberarzt) of the hemato-
oncological department 2B**
since 05-2006 **Austrian representative in the IBFM Executive Board**

AWARDS:

- 1995 Wissenschaftspreis 1995 für pädiatrische Hämatologie und Onkologie der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde
- 1999 Theodor-Billrothpreis-Preis d. Ärztekammer f. Wien
- 2003 Wissenschaftspreis 2003 für pädiatrische Hämatologie und Onkologie der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde

GRANTS:

- 1995 Histiocytosis Association of America; US \$ 10 000,-
Project: "Bone marrow involvement in patients with multi-system Langerhans cell histiocytosis"
- 2004 Österreichische Nationalbank – Jubiläumsfonds Nr. 10962
€ 60 000,-; Project: „Durchflusszytometrische MRD-Bestimmung bei Kindern mit ALL“
- 2005 Fonds zur Förderung der wissenschaftlichen Forschung
FWF P18196-B05; € 209 889,75 (3 years)
Project: „Funktion von CD99 in der B-Zell Entwicklung“
- 2007 Wiener Wissenschafts-, Forschungs-, und Technologie
Fonds „Linking Research and Patients' Needs" Call 2007
WWTF Nr. LS07-037; € 654 500,- (4 years)
Project: "Flow cytometric signal typing for therapy response prediction in pediatric myeloid leukaemia"

LIST OF PUBLICATIONS - Michael N. Dworzak

- 1) Kovar H., **Dworzak M.**, Strehl S., Schnell E., Ambros I.M., Gadner H., Ambros P.F. (1990) Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumors. ***Oncogene 5: 1067-1070***
- 2) **Dworzak M.**, Stock C., Strehl S., Gadner H., Ambros P.F. (1992) Ewing's tumor x mouse hybrids expressing the MIC2 antigen: analyses using fluorescence CDD-banding and non-isotopic ISH. ***Human Genetics 88: 273-278***
- 3) Fuchs P., Strehl.S., **Dworzak M.**, Himmeler A., Ambros P.F. (1992) Structure of the human TNF receptor 1 gene and localization to chromosome 12p13. ***Genomics 13: 219-224***
- 4) **Dworzak M.N.**, Fritsch G., Buchinger P., Fleischer C., Printz D., Zellner A., Schöllhammer A., Steiner G., Ambros P.F., Gadner H. (1994) Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. ***Blood 83(2): 415-425***
- 5) Fritsch G., Ströbel T., **Dworzak M.N.**, Buchinger P., Printz D., and Gadner H. (1994) Single and multicolor flow cytometric CD34 analysis in different cell sources. ***Progress in Clinical Biology Research 389: 325-330***
- 6) Fritsch G., Buchinger P., Printz D., **Dworzak M.N.**, Strunk S., Agis G., Sliutz G., Wilfing A., Schulz U., and Gadner H. (1994) Is CD33 a differentiation marker? ***Progress in Clinical Biology Research 389: 377-382***
- 7) Zoubek A., Pfeleiderer C., Ambros P.F., Kronberger M., **Dworzak M.N.**, Gruber B., Luegmayer A., Windhager R., Fink F.M., Urban C., Koscielniak E., Gadner H., and Kovar H. (1995) Minimal metastatische - und minimal residuelle Erkrankung bei Patienten mit Ewing-Tumoren. ***Klinische Pädiatrie 207: 242-247***
- 8) **Dworzak M.N.**, Fritsch G., Fleischer C., Printz D., Fröschl G., Buchinger P., Mann G., and Gadner H. (1997) Multiparameter phenotype mapping of normal and post-chemotherapy B-lymphopoiesis in pediatric bone marrow. ***Leukemia 11: 1266-1273***
- 9) Fritsch G., Printz D., Stimpfl M., **Dworzak M.N.**, Witt V., Pötschger U., and Buchinger P. (1997) Quantification of CD34+ cells: comparison of methods. ***Transfusion 37: 775-784***
- 10) **Dworzak M.N.**, Fritsch G., Fleischer C., Printz D., Fröschl G., Buchinger P., Mann G., and Gadner H. (1998) Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. ***Experimental Hematology 26: 305-313***
- 11) **Dworzak M.N.**, Fritsch G., Fröschl G., Printz D., and Gadner H. (1998) Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. ***Blood 92(9): 3203-3209***

- 12) Dworzak M.N.**, Stolz F., Fröschl G., Printz D., Henn T., Fischer S., Fleischer C., Haas O.A., Fritsch G., Gadner H., and Panzer-Grümayer E.R. (1999) Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods. *Experimental Hematology* **27**: 673-681
- 13) Dworzak M.N.**, Fröschl G., Printz D., Fleischer C., Pötschger U., Fritsch G., Gadner H., and Emminger W. (1999) Skin-associated lymphocytes in the peripheral blood of patients with atopic dermatitis: signs of subset expansion and stimulation. *Journal of Allergy and Clinical Immunology* **103**: 901-906
- 14) Dworzak M.N.**, Fritsch G., Fleischer C., Printz D., Fröschl G., Buchinger P., Mann G., and Gadner H. (1999) CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. *British Journal of Haematology* **105**: 690-695
- 15) Aberle J.H.**, Aberle S.W., **Dworzak M.N.**, Mandl C.W., Rebhandl W., Vollnhofer G., Kundi M., Popow-Kraupp T. (1999) Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. *American Journal Respiration Critical Care Medicine* **160(4)**:1263-1268
- 16) Dworzak M.N.**, Fritsch G., Panzer-Grümayer E.R., Mann G., and Gadner H. (2000) Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance. *Leukemia and Lymphoma* **38(3-4)**: 295-308
- 17) Dworzak M.N.** (2001) Immunological detection of minimal residual disease in acute lymphoblastic leukaemia. (Review) *Onkologie* **24**:442-448
- 18) Dworzak M.N.**, Fröschl G., Printz D., Mann G., Pötschger U., Mühlegger N., Fritsch G., and Gadner H. (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. *Blood* **99(6)**:1952-1958
- 19) Attarbaschi A.**, Mann G., **Dworzak M.N.**, Urban C., Fink F.M., Dieckmann K., Riehm H.J., and Gadner H. for the Austrian Cooperative Study Group (2002) Treatment results of childhood acute lymphoblastic leukaemia in Austria – a report of 20 years' experience. *Wiener Klinische Wochenschrift* **114(4)**:148-157
- 20) Mann G.**, Trebo M.M., Haas O.A., Grümayer-Panzer E.R., **Dworzak M.N.**, Lion T., and Gadner H. (2002) Philadelphia chromosome-positive mature B-cell (Burkitt-cell) leukaemia. *British Journal of Haematology* **118**:559-562
- 21) Attarbaschi A.**, Mann G., **Dworzak M.N.**, Wiesbauer P., Schrappe M., and Gadner H. (2002) Mediastinal mass in childhood T-cell acute lymphoblastic leukaemia: significance and therapy response. *Medical Pediatric Oncology* **39**:558-565
- 22) Attarbaschi A.**, Mann G., **Dworzak M.N.**, Trebo M., Mühlegger N., Reiter A., Horcher E., and Gadner H. for the Austrian Cooperative Study Group (2002) The role

of surgery in the treatment of pediatric B-cell Non-Hodgkin's lymphoma. *Journal Pediatric Surgery* **37:1470-1475**

23) Attarbaschi A., Mann G., **Dworzak M.N.**, Trebo M., Urban C., Fink F.M., Horcher E., Reiter A., Riehm H.J., and Gadner H. on behalf of the Austrian Cooperative Study Group **(2002)** Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria – Therapy results between 1986 and 2000. *Wiener Klinische Wochenschrift* **114(23-24):978-986**

24) Reinhardt D., Langebrake C., Creutzig U., Vormoor J., Brune C., Thorwesten, M., Ingiliz P., Hrusak O., **Dworzak M.N.**, Griesinger F. **(2002)** Minimal residual disease in acute myeloid leukaemia in children – standardization and evaluation of immunophenotyping in the AML-BFM-98 study. *Klinische Pädiatrie* **214:179-187**

25) **Dworzak M.N.**, Panzer-Grümayer E.R. **(2003)** Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. *Leukemia and Lymphoma* **44:1445-1455**

26) Strehl S., König M., **Dworzak M.N.**, Kalwag K., Haas O.A. **(2003)** PAX5/ETV6 fusion defines cytogenetic entity dic (9;12)(p13;p13). *Leukemia* **17:1121-1131**

27) Attarbaschi A., Mann G., Kronberger M., Witt V., Gadner H., **Dworzak M.N.** **(2003)** Effects of Dose-Reduced MEDAC- L-Asparaginase on Coagulation in Trial ALL-BFM 2000 - Gerinnungsveränderungen unter Dosis-reduzierter Medac-L-Asparaginase in der Studie ALL-BFM 2000. *Klinische Pädiatrie* **215:321–326**

28) Veltroni M., De Zen L., Sanzari M. C., Maglia O., **Dworzak M.N.**, Ratei R., Biondi A., Basso G., Gaipa G., on behalf of the I-BFM-ALL-FCM-MRD-Study Group **(2003)** Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. *Haematologica* **88:1245-1252**

29) Trebo M.M., Mann G., **Dworzak M.**, Zoubek A., Gadner H. **(2003)** Wilms tumor and cardiomyopathy. *Medical Pediatric Oncology* **41:574**

30) **Dworzak M.N.**, Fröschl G., Printz D., De Zen L., Gaipa G., Ratei R., Basso G., Biondi A., Ludwig W.D., and Gadner H., on behalf of the I-BFM-ALL-FCM-MRD-Study Group **(2004)** CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. *Leukemia* **18:703-708**

31) Reinhardt D., Diekamp S., Fleischhack G., Corbacioglu S., Jürgens H., **Dworzak M.**, Kaspers G., Creutzig U., Zwaan C.M. **(2004)** Gemtuzumab Ozogamicin (Mylotarg®) in children with refractory or relapsed acute myeloid leukemia. *Onkologie* **27:269-272**

32) Attarbaschi A., **Dworzak M.**, Steiner M., Urban C., Fink F.-M., Reiter A., Gadner H., Mann G. **(2004)** Outcome of children with primary resistant or relapsed Non-Hodgkins lymphoma and mature B-cell leukemia after intensive first-line treatment: a

population-based analysis of the Austrian Cooperative Study Group. *Pediatr Blood Cancer* **43:1–7**

33) Attarbaschi A., Mann G., König M., **Dworzak M.N.**, Trebo M.M., Mühlegger N., Gadner H., and Haas O.A. on behalf of the Austrian Berlin-Frankfurt-Münster (BFM) Cooperative Study Group **(2004)** Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. *Leukemia* **18:1611-1616**

34) Creutzig U., Zimmermann M., Reinhardt D., **Dworzak M.**, Stary J., Lehrnbecher T. **(2004)** Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. *J Clin Oncol* **22:4384-4393**

35) Gaipa G., Basso G., Maglia O., Leoni V., Faini A., Cazzaniga G., Bugarin C., Veltroni M., Michelotto B., Ratei R., Coliva T., Valsecchi M.G., Biondi A., **Dworzak M.N.** on behalf of the I-BFM-ALL-FCM-MRD-Study Group **(2005)** Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. *Leukemia* **19:49-56**

36) Mlczoch L., Attarbaschi A., **Dworzak M.N.**, Gadner H., and Mann G. **(2005)** Alopecia areata and multifocal bone involvement in a young adult with Hodgkin's disease. *Leukemia & Lymphoma* **46:623-627**

37) Nebral K., König M., Schmidt H.H., Lutz D., Sperr W.R., Kalwak K., Brugger S., **Dworzak M.N.**, Haas O.A., Strehl S. **(2005)** Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. *Haematologica* **90:746-752**

38) Creutzig U., Reinhardt D., Diekamp S., **Dworzak M.**, Stary J., Zimmermann M. **(2005)** AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. *Leukemia* **19:1355-1360**

39) Reinhardt D., Diekamp S., Langebrake C., Ritter J., Stary J., **Dworzak M.**, Schrauder A., Zimmermann M., Fleischhack G., Ludwig W.-D., Harbott J., Creutzig U. **(2005)** Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. *Leukemia* **19:1495–1496**

40) Attarbaschi A., Mann G., König M., Steiner M., Strehl S., Schreiberhuber A., Schneider B., Meyer C., Marschalek R., Borkhardt A., Pickl W. F., Lion T., Gadner H., Haas O.A. and **Dworzak M.N.** on behalf of the Austrian Berlin-Frankfurt-Münster (BFM) Cooperative Study Group **(2006)** MLL-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukaemia constitute a distinct clinical entity. *Clinical Cancer Research* **12(10):2988-2994**

41) Groll A. H., Attarbaschi A., Schuster F. S., Herzog N., Grigull L., **Dworzak M. N.**, Beutel K., Laws H.-J. and Lehrnbecher T. **(2006)** Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. *Journal of Antimicrobial Chemotherapy* **57(3):527-535**

- 42)** Mann G., Attarbaschi A., Steiner M., Simonitsch I., Strobl H., Urban C., Meister B., Haas O., **Dworzak M.** and Gadner H. on behalf of the Austrian Berlin–Frankfurt–Münster (BFM) Group **(2006)** Early and reliable diagnosis of Non-Hodgkin lymphoma in childhood and adolescence: Contribution of cytomorphology and flow cytometric immunophenotyping. ***Pediatric Hematology and Oncology, 23:167–176***
- 43)** Attarbaschi A., Mann G., König M., Steiner M., **Dworzak M.N.**, Gadner H. and Haas O.A. **(2006)** Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases. ***Genes Chromosomes Cancer, 45(6):608-611***
- 44)** Langebrake C., Creutzig U., **Dworzak M.**, Hrusak O., Mejstrikova E., Griesinger F., Zimmermann M. and Reinhardt D. **(2006)** Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM Study Group. ***Journal of Clinical Oncology, 24(22):3686-3692***
- 45)** Creutzig U., Zimmermann M., Lehrnbecher T., Graf N., Hermann J., Niemeyer C.M., Reiter A., Ritter J., **Dworzak M.**, Sary J., and Reinhardt D. **(2006)** Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98. ***Journal of Clinical Oncology, 24(27):4499-4506***
- 46)** Steiner M., Attarbaschi A., Kastner U., **Dworzak M.**, Haas O.A., Gadner H., and Mann G. **(2007)** Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukaemia. ***Pediatric Blood and Cancer, 49(5):640-642***
- 47)** Lehrnbecher T., Zimmermann M., Reinhardt D., **Dworzak M.**, Sary J., Creutzig U. **(2007)** Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. ***Blood, 109:936-943***
- 48)** Attarbaschi A., Mann G., Strehl S., König M., Steiner M., Jeitler V., Lion T., **Dworzak M.N.**, Gadner H., and Haas O.A. on behalf of the Austrian Berlin-Frankfurt–Münster (BFM) Cooperative Study Group **(2007)** Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukaemia. ***Leukemia, 21(3):584-586***
- 49)** Attarbaschi A., Mann G., Schumich A., König M., Pickl W.F., Haas O.A., Gadner H., and **Dworzak M.N.** **(2007)** CD44 deficiency is a consistent finding in childhood Burkitt’s lymphoma and leukaemia. ***Leukemia, 21(5):1110-1113***
- 50)** Minkov M., Pötschger U., Grois N., Gadner H., **Dworzak M.N.** **(2007)** Bone marrow assessment in Langerhans cell histiocytosis. ***Pediatric Blood and Cancer, 49(5):694-698***
- 51)** Kager L., Lion T., Attarbaschi A., Koenig M., Strehl S., Haas O.A., **Dworzak M.N.**, Schrappe M., Gadner H., and Mann G. for the Austrian BFM Study Group **(2007)** Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. ***Haematologica, 92:1561-1564***

- 52)** Felder-Puig R., Scherzer C., Baumgartner M., Ortner M., Aschenbrenner C., Bieglmayer C., Voigtlaender T., Panzer-Gruemayer E.R., Tissing W.J.E., Koper J.W., Steinberger K., Nasel C., Gadner H., Topf R., and **Dworzak M. (2007)** Glucocorticoids in the treatment of children with acute lymphoblastic leukemia and Hodgkin's disease: A pilot study on the adverse psychological reactions and possible associations with neurobiological, endocrine, and genetic markers. *Clinical Cancer Research*, **13(23): 7093-7100**
- 53)** Huhulescu S., Schmid D., Mayer B., Stadlbauer S., Wewalka G., Allerberger F., and **Dworzak M. (2008)** Partial teicoplanin dependence in a vancomycin-dependent *Enterococcus faecium* isolated from an oncology patient one month after cessation of teicoplanin therapy. *International Journal of Antimicrobial Agents*, **31: 76-90**
- 54)** Fazekas T., Wiesbauer P., Kronberger M., Wank H., Gadner H., **Dworzak M. (2008)** Nodular pulmonary lesions in children after autologous stem cell transplantation: a source of misinterpretation. *British Journal of Haematology*, **140: 429-432**
- 55)** Klusmann J.H., Creutzig U., Zimmermann M., **Dworzak M.**, Jorch N., Langebrake C., Pekrun A., Macakova-Reinhardt K., Reinhardt D. **(2008)** Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. *Blood* **111: 2991-2998**
- 56)** Gaipa G., Basso G., Aliprandi S., Migliavacca M., Vallinoto C., Maglia O., Faini A., Veltroni M., Husak D., Schumich A., Ratei R., Biondi A., **Dworzak M.N.**, on behalf of the I-BFM-ALL-FCM-MRD-Study Group **(2008)** Prednisone induces immunophenotypic modulation of CD10 and CD34 in non-apoptotic B-cell precursor acute lymphoblastic leukemia cells. *Cytometry B Clin Cytom.* **74: 150-155**
- 57)** **Dworzak M.N.**, Gaipa G., Ratei R., Veltroni M., Schumich A., Maglia O., Karawajew L., Benetello A., Pötschger U., Husak Z., Gadner H., Biondi A., Ludwig W.D., Basso G. **(2008)** Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. *Cytometry B Clin Cytom.* **2008 published online Jun 11.**
- 58)** Attarbaschi A., Mann G., Panzer-Grümayer R., Röttgers S., Steiner M., König M., Csinady E., **Dworzak M.N.**, Seidel M., Janousek D., Möricke A., Reichelt C., Harbott J., Schrappe M., Gadner H., Haas O.A. **(2008)** Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) trials. *Journal of Clinical Oncology* **26:3046-3050**
- 59)** Lehrnbecher T., Laws H.J., Boehm A., **Dworzak M.**, Janssen G., Simon A., Groll A.H. **(2008)** Compliance with anti-infective preventive measures: A multicentre survey among paediatric oncology patients. *European Journal of Cancer.* **2008 Jul 26. [Epub ahead of print]**
- 60)** **Dworzak M.N.**, Schumich A., Printz D., Pötschger U., Husak Z., Attarbaschi A., Basso G., Gaipa G., Ratei R., Mann G., Gadner H. for the AIEOP-BFM-ALL-FCM-

MRD-Study Group (2008) CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immuno-therapy. *Blood. In press*

PUBLISHED ABSTRACTS (*Selection*)

2003 – American Society of Hematology

Ursula Creutzig, Dirk Reinhardt, Martin Zimmermann, **Michael Dworzak**, Jan Sary Ped. Hematology/Onkology, Univ. Childrens Hospital Muenster, Muenster, Germany; St. Anna Kinderspital and CCRI, Wien, Austria; 2. Medical Faculty, 2. Dep. Pediatrics, Charles University, Prag, Czech Republic

Excellent Results In Patients With Down's Syndrome by Standard AML-BFM Therapy with Reduced Drug Intensity.

Blood, Volume 102, issue 11, abs[4714] November 16, 2003

2004 – American Society of Hematology

ORAL SESSIONS:

Dirk Reinhardt, Sylke Diekamp, Joerg Ritter, Claudia Langebrake, Gudrun Fleischhack, **Michael Dworzak**, Jan Sary, Jochen Harbott, Wolf-Dieter Ludwig, and Ursula Creutzig
Acute Megakaryoblastic Leukemia in Children without Down's Syndrome.
Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 401.

POSTER SESSIONS:

Richard Ratei, Mathilde Martin, Guiseppa Basso, Guiseppa Gaipa, Martin Schrappe, **Michael Dworzak**, Wolf-Dieter Ludwig, and Leonid Karawajew
MRD-Detection by Multiparametric Flow Cytometry in Childhood Precursor B-Cell All: Predictive Impact of Early Blast Reduction Kinetics in Peripheral Blood (PB) on MRD-Level in Bone Marrow (BM) at Day 33 of the All-BFM2000 Potocol.
Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 987.

POSTER SESSIONS:

Giuseppe Gaipa, Marinella Veltroni, Richard Ratei, Wolf-Dieter Ludwig, Andrea Biondi, Giuseppe Basso, and **Michael N. Dworzak**
Feasibility of Multicentric Assessment of MRD in All by Flow-Cytometry: Standardization and Experience of the I-BFM-ALL FCM-MRD Study Group.
Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 1079.

POSTER SESSIONS:

Thomas Lehrnbecher, Martin Zimmermann, Dirk Reinhardt, **Michael Dworzak**, Jan Sary, and Ursula Creutzig
Impact of Granulocyte Colony-Stimulating Factor during Induction Therapy in Children with Acute Myelogenous Leukemia: Results from the Prospective and Randomized Trial AML-BFM 98.
Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 2911.

ABSTRACTS NOT SELECTED FOR PRESENTATION:

Thomas Lehrnbecher, Andishe Attarbaschi, Friedhelm Schuster, Nadine Herzog, Lorenz Grigull, **Michael Dworzak**, Karin Beutel, Hans-Jürgen Laws, and Andreas H. Groll
Clinical Use of Caspofungin in Immunocompromised Children: A Multicenter Survey.
Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 5066.

2005 – American Society of Hematology

ORAL SESSIONS:

Claudia Langebrake, **Michael Dworzak**, Ondrej Hrusak, Ester Mejstrikova, Frank Griesinger, Martin Zimmermann, Ursula Creutzig, and Dirk Reinhardt
Minimal Residual Disease Monitoring by Four Color Flow Cytometry before Second Induction Is an Independent Prognostic Factor in Childhood Acute Myeloid Leukemia - AML-BFM MRD Study Group.
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 671.

POSTER SESSIONS:

Leo Kager, Thomas Lion, Andishe Attarbaschi, Margit Koenig, Sabine Strehl, Oskar A. Haas, **Michael N. Dworzak**, Martin Schrappe, Helmut Gadner, and Georg Mann
Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 1458.

POSTER SESSIONS:

Gertjan J. Kaspers, M. Zimmermann, G. Fleischhack, R. Tamminga, B. Gibson, H. Armendariz, **M. Dworzak**, S. Ha, L. Hovi, A. Maschan, N. Philippe, B. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, and U. Creutzig
Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Results of the International Randomised Phase III Study "Relapsed AML 2001/01".
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 897.